Can-Fite BioPharma (NYSE:CANF) CEO Pnina Fishman speaks to Proactive's Thomas Warner about her hopes for two new treatments the company is developing during 2023.
She reveals the drugs that Can-Fite is currently developing and lays out her plans for the coming year, saying that two treatments are "very close" to entering the clinic.